Biota Pharmaceuticals

The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial. 
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Alpharetta, US
Size (employees)
19 (est)
Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US

Biota Pharmaceuticals Office Locations

Biota Pharmaceuticals has an office in Alpharetta
Alpharetta, US (HQ)
100 2500 Northwinds Pkwy

Biota Pharmaceuticals Data and Metrics

Biota Pharmaceuticals Financial Metrics

Biota Pharmaceuticals's revenue was reported to be $4.9 m in Q3, 2017

Revenue (Q3, 2017)

4.9 m

Net income (Q3, 2017)

(4.4 m)

EBIT (Q3, 2017)

(3.8 m)

Cash (31-Mar-2017)

11.8 m
USDFY, 2014FY, 2015FY, 2016


68.7 m24.6 m9.3 m

Revenue growth, %


Cost of goods sold

51.1 m3.6 m

Gross profit

17.6 m21 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


700 k13.9 m5.9 m1.7 m1.7 m5.3 m100 k3.8 m4.9 m

Cost of goods sold

1.7 m1.6 m300 k

Gross profit

(1 m)12.3 m5.6 m

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


81.7 m44.7 m49.7 m

Current Assets

101.1 m70.8 m72.4 m


2 m200 k300 k

Total Assets

114 m79.4 m72.7 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


57.7 m63.7 m61.5 m45.3 m39 m30.6 m45.9 m38.1 m11.8 m

Accounts Receivable

10.1 m3.2 m

Current Assets

76.1 m86.2 m87.4 m61.2 m58.6 m60.5 m62.8 m56.2 m46.4 m


1.6 m1.1 m300 k200 k400 k400 k300 k300 k300 k
USDFY, 2014FY, 2015FY, 2016

Net Income

(11 m)(19.1 m)(25.4 m)

Depreciation and Amortization

2.4 m1.1 m100 k

Accounts Receivable

(7.1 m)6.2 m11.9 m

Cash From Operating Activities

(3.3 m)(9.6 m)(14.1 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(6.9 m)6.5 m1.2 m(6.6 m)(6.5 m)(5.2 m)(10 m)(9.1 m)(4.4 m)

Accounts Receivable

10.1 m3.2 m

Accounts Payable

1.4 m1.7 m1 m2.9 m1.3 m3.7 m1.6 m3.4 m1.8 m
Y, 2017

Financial Leverage

1.9 x
Show all financial metrics

Biota Pharmaceuticals Operating Metrics

FY, 2016

Phase II Trials


Marketed Vaccines

Show all operating metrics

Traffic Overview of Biota Pharmaceuticals

Biota Pharmaceuticals Company Life and Culture

You may also be interested in